DR   cancercelllines; CVCL_DG28
DR   Wikidata; Q54938488
RX   PubMed=26980747;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
CC   Selected for resistance to: ChEBI; CHEBI:61400; WZ4002.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 13
RX   PubMed=26980747; DOI=10.18632/oncotarget.8013;
RA   Park J.H., Choi Y.J., Kim S.Y., Lee J.-E., Sung K.J., Park S.,
RA   Kim W.S., Song J.S., Choi C.-M., Sung Y.H., Rho J.K., Lee J.C.;
RT   "Activation of the IGF1R pathway potentially mediates acquired
RT   resistance to mutant-selective 3rd-generation EGF receptor tyrosine
RT   kinase inhibitors in advanced non-small cell lung cancer.";
RL   Oncotarget 7:22005-22015(2016).